I’m not sure I believe this, but here ya go:
“A new class of diabetes drugs can protect kidney health in addition to lowering blood sugar levels, study results suggest.
The findings, published August 18 in the Journal of the American Society of Nephrology, investigated the renal effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, specifically canagliflozin, which reduce blood sugar by augmenting the excretion of glucose into urine.
“Since glycemic control is only modestly different between canagliflozin and glimepiride, our results suggest that potential kidney protective effects of canagliflozin may be unrelated to glycemic control,” the lead study author, Hiddo Lambers Heerspink, PhD, of the University Medical Center Groningen in the Netherlands, said in a statement.”
PS: Even if these results are reproducible, remember that they may not apply to all drugs in the SGLT2 inhibitor class.